Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. develops the Nautilus Voyager proteomics platform, an integrated system that combines instruments, consumables, and software analysis for large-scale protein analysis. The company is based in the United States and operates as a development-stage life sciences tools business with its platform still under development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueThe Nautilus Voyager instrument automates assay chemistry and optical imaging for proteomics workflows.
Reagents and run-based consumables used with the Nautilus platform.
Software tools used to process and analyze proteomics data generated by the platform.
Controlled access to the platform through service laboratory operations and early customer workflows.
Customers
Nautilus targets research customers that already work in proteomics or adjacent multi-omics workflows and need higher-resolution protein analysis tools. Initial buyers include large pharmaceutical and biotechnology companies, academic research institutions, and multi-omics research centers, with future expansion into translational research, clinical development groups, CROs, and diagnostic laboratories.
Buy platform access and future instruments to support discovery, biomarker, and translational proteomics work.
Use the platform for research programs that need multiplexed protein measurement and workflow automation.
Purchase access for basic and applied proteomics research funded by grants and institutional budgets.
Adopt the platform to combine proteomics with other omics datasets in specialized research programs.
Potential future users for translational studies and outsourced research services as the platform matures.
Strategy
Nautilus is pursuing a phased commercialization model that starts with service-based access and limited system exposure before broader instrument deployment. The company is also building sales, marketing, distribution, manufacturing, and intellectual property capabilities to support eventual scale-up of the Nautilus Voyager platform.
A controlled rollout helps refine workflows and reduce early adoption risk.
Sales, marketing, service, and distribution capabilities are needed for market entry.
The platform must complete technical development and testing before broad commercialization.
Patents and know-how help protect the platform in a competitive proteomics market.
Geography
Nautilus is headquartered in the United States and currently assembles systems in San Carlos, California, using external manufacturers and in-house integration. The company plans to commercialize first in the United States and then through direct and distributor channels in the European Union, the United Kingdom, and potentially Asia-Pacific markets.
Risks
Nautilus is a development-stage company with no commercial product revenue, so its business depends on successfully completing development and gaining market acceptance for the Nautilus platform. It also faces execution risk from third-party manufacturing, commercialization timing, and competition from established life sciences tools companies and emerging proteomics developers.
- Development-stage business riskImpact: CriticalLikelihood: High
The company has not commercialized products and may never reach profitable scale.
Exposure: Entire business
- Platform commercialization delayImpact: HighLikelihood: High
Launch timing depends on technical validation, customer adoption, and operational readiness.
Exposure: Nautilus Voyager platform
- Competitive pressureImpact: HighLikelihood: Medium
Established tools companies and emerging proteomics firms may outpace Nautilus in productization and sales.
Exposure: Proteomics market
- Third-party manufacturing dependenceImpact: MediumLikelihood: Medium
Key components are sourced externally and assembly may rely on partners, creating supply and quality risk.
Exposure: Instrumentation supply chain
- Customer funding sensitivityImpact: MediumLikelihood: Medium
Demand depends on research spending by pharma, biotech, and academic institutions.
Exposure: End-market demand
Accounting
Judgemental itemsDevelopment-stage spending is the main cost line and drives reported losses.
Impact: Affects operating loss and cash burn
Employee equity awards are a recurring non-cash expense in a talent-intensive business.
Impact: Affects operating expenses and dilution analysis
As service access, instruments, consumables, and software are commercialized, timing of recognition will matter.
Impact: Could affect quarterly comparability and gross margin presentation
Scale-up of instrument production may require inventory valuation and reserve judgments.
Impact: Could affect cost of revenue and working capital
Similar listed companies
Publicly listed companies with a comparable business focus.
Nauticus Robotics, Inc.
KITTW · General Industrial Machinery & Equipment, NEC
Standard BioTools Inc
LAB · Pharmaceutical Preparations
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Seer, Inc.
SEER · Laboratory Analytical Instruments
Recursion Pharmaceuticals, Inc
RXRX · Biological Products, (No Diagnostic Substances)
Recursion Pharmaceuticals is a U.S.-based clinical-stage TechBio company that uses its Recursion Operating System to discover and develop medicines.
Last updated: 24/09/2026